EUVIMEDEUVIMED entdecken
Open Access

Real‐world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single‐centre experience

Taku Kikuchi iD, Ukyo Kondo, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo iD, Kodai Kunisada, Kota Sato, Tomomi Takei, Yu Abe, Osamu Hosoya, Tadao Ishida und 1 weitere

British Journal of Haematology · 2026-08 · 209 (2) · 782-785

DOI: 10.1111/bjh.70602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 02.06.2026. Verfasst von Taku Kikuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

stage IV at infusion had markedly inferior PFS, supporting the clinical relevance of treatment-time (dynamic) risk assessment and warranting validation in larger cohorts. This is consistent with the emerging concept of the ‘dynamic’ R2-ISS as a prognostic tool across treatment settings. 15 This study has several limitations. First, its retrospective, single-centre design may introduce selection bias, particularly given the low tumour burden at infusion, minimal prior BCMA exposure and universal use of bridging therapy in this cohort. In addition, the median follow-up remains relatively short compared with the estimated median PFS, necessitating longer observation to confirm the durability of these outcomes. Finally, BCMA expression and soluble BCMA could not be evaluated in this study and warrant further investigation. In conclusion, although these findings should be interpreted with caution, the favourable outcomes observed in our cohort may be associated with the earlier use of ide-cel, patient selection and disease control prior to ide-cel infusion and warrant validation in larger, multicentre real-world studies.

Schlagwörter

Stichwörter der Autor:innen

idecabtagene vicleucelmultiple myelomareal‐world outcomes

Autor:innen und Institutionen

  • Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.

ORCID-Profile: Taku Kikuchi, Moe Nomura-Yogo

Zitieren

APA

Kikuchi, T., Kondo, U., Sugita, S., Watanabe, M., Matsumoto, C., Nomura-Yogo, M., Kunisada, K., Sato, K., Takei, T., Abe, Y., Hosoya, O., Ishida, T., & Tsukada, N. (2026). Real‐world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single‐centre experience. British Journal of Haematology, 209(2), 782-785. https://doi.org/10.1111/bjh.70602

Vancouver

Kikuchi T, Kondo U, Sugita S, Watanabe M, Matsumoto C, Nomura-Yogo M, et al. Real‐world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single‐centre experience. British Journal of Haematology. 2026;209(2):782-785. doi:10.1111/bjh.70602

BibTeX
@article{Kikuchi2026,
  author = {Kikuchi, Taku and Kondo, Ukyo and Sugita, Shotaro and Watanabe, Miyu and Matsumoto, Chiaki and Nomura-Yogo, Moe and Kunisada, Kodai and Sato, Kota and Takei, Tomomi and Abe, Yu and Hosoya, Osamu and Ishida, Tadao and Tsukada, Nobuhiro},
  title = {Real‐world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single‐centre experience},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {2},
  pages = {782--785},
  doi = {10.1111/bjh.70602}
}
Kostenlos starten →